An AI-Driven Framework for Discovery of BACE1 Inhibitors for Alzheimer’s Disease

Evan Xie, Karin Hasegawa, Georgios Kementzidis, Evangelos Papadopoulos, Bertal H. Aktas, Yuefan DengbioRxiv 2024 · DOI

TL;DR

This paper introduces a novel AI framework for discovering new BACE1 inhibitors for Alzheimer's disease. By combining advanced generative AI techniques with molecular docking, the framework successfully generated over a million novel drug candidates, identifying 14 promising compounds with superior binding affinities to the BACE1 target compared to existing drugs.

What Problem Does This Paper Address?

Alzheimer's Disease (AD) is a devastating neurodegenerative disorder affecting millions worldwide. A key player in AD pathology is the BACE1 enzyme, which produces amyloid-beta (Aβ) plaques in the brain. Inhibiting BACE1 is a promising therapeutic strategy, but previous attempts have been hampered by issues like poor blood-brain barrier (BBB) permeability and molecular size limitations. Developing new BACE1 inhibitors that are effective, can cross the BBB, and are synthetically accessible has been a significant challenge. Traditional drug discovery methods are often time-consuming, expensive, and limited by human knowledge, leading to a high failure rate for drug candidates.

Methods

The authors developed a multi-stage generative AI framework:

  • Molecular Representation: They utilized the SELFIES (Self-Referencing Embedded Strings) notation, a robust method that ensures generated molecular strings always represent chemically valid molecules, addressing a key limitation of older methods like SMILES.
  • Autoencoder: A deep learning autoencoder was employed to convert SELFIES strings into continuous latent vectors. This simplified representation captures essential molecular information and allows subsequent models to operate efficiently in a lower-dimensional space.
  • Generative Adversarial Network (WGAN-GP): A Wasserstein Generative Adversarial Network with Gradient Penalty (WGAN-GP) was used to learn the distributions of known BACE1 inhibitors and generate novel candidate molecules with similar properties. WGAN-GP is chosen for its robustness in avoiding common GAN training issues.
  • Molecular Property Predictors: Quantitative Structure-Activity Relationship (QSAR) models were trained to predict key properties like inhibitory activity (pIC50), molecular weight (MW), and lipophilicity (LogP). These predictors operate on the latent vectors.
  • Genetic Algorithm (GA): A GA was integrated to optimize the generated compounds for improved inhibitory activity and BBB permeability. It uses a fitness function based on pIC50, MW, and LogP, employing selection schemes like elitism and roulette.
  • Molecular Docking Validation: The top candidate compounds were evaluated using AutoDock Vina to simulate their binding interactions with the BACE1 active site, comparing them against existing BACE1 drugs.

Datasets

  • ChEMBL 33 Database: This database was the primary source for molecular data.
  • A general dataset containing 2,372,674 molecules was used to represent the broader chemical space.
  • A targeted dataset containing 10,619 known BACE1 inhibitors was used to learn specific properties of effective inhibitors.

Key Insights and Ideas

  • SELFIES for Robustness: Using SELFIES notation significantly improves the chemical validity of generated molecules, a critical step for reliable de novo drug discovery.
  • Latent Space Efficiency: Representing molecules as latent vectors from an autoencoder provides a simplified yet informative input for downstream AI models, outperforming traditional molecular descriptors.
  • WGAN-GP for Novelty: The WGAN-GP, trained on SELFIES, demonstrated a remarkable ability to generate valid, unique, and novel compounds, surpassing previous AI models.
  • GA for Targeted Optimization: The Genetic Algorithm effectively fine-tuned generated molecules for improved potency and BBB permeability, addressing key limitations of earlier BACE1 inhibitors.
  • Synergy of AI and Docking: The combination of generative AI for discovery and molecular docking for validation proved highly effective in identifying promising drug candidates.

Key Results

  • The framework generated over 1,000,000 candidate inhibitors.
  • 14 candidate drugs were identified that exhibited stronger binding interactions to the BACE1 active site than four terminated BACE1 drugs from clinical trials.
  • The WGAN-GP achieved high scores for validity (up to 100%), uniqueness (up to 99.3%), and novelty (up to 99.1%).
  • The GA optimization improved the fitness scores of generated compounds, leading to molecules with better inhibitory activity and BBB permeability.
  • Molecular docking simulations showed that three generated compounds had more favorable binding energies than all four terminated BACE1 drugs.

Limitations and Future Work

  • Targeted Dataset Size: The WGAN-GP's ability to fully capture molecular property distributions was limited by the relatively small size of the targeted BACE1 inhibitor dataset. Future work could explore data augmentation techniques.
  • Drug-likeness and Synthesizability: A majority of the initially discovered compounds did not have favorable SAS (Synthetic Accessibility) and QED (Quantitative Estimate of Drug-Likeness) values. Future work could incorporate these metrics directly into the GA fitness function for optimization.
  • Experimental Validation: The identified candidate drugs require further testing through later stages of the drug design pipeline, including molecular dynamics simulations, chemical synthesis, in vitro assays, and clinical trials.
  • Generalizability: The framework's adaptability to other therapeutic targets is highlighted, requiring only minor modifications to retrain the pIC50 predictor on new datasets.

Summary updated

Abstract

Abstract Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder that affects over 51 million individuals globally. The β -secretase (BACE1) enzyme is responsible for the production of amyloid beta (A β ) plaques in the brain. The accumulation of A β plaques leads to neuronal death and the impairment of cognitive abilities, both of which are fundamental symptoms of AD. Thus, BACE1 has emerged as a promising therapeutic target for AD. Previous BACE1 inhibitors have faced various issues related to molecular size and blood-brain barrier permeability, preventing any of them from maturing into FDA-approved AD drugs. In this work, a generative AI framework is developed as the first AI application to the de novo generation of BACE1 inhibitors. Through a simple, robust, and accurate molecular representation, a Wasserstein Generative Adversarial Network with Gradient Penalty (WGAN-GP), and a Genetic Algorithm (GA), the framework generates and optimizes over 1,000,000 candidate inhibitors that improve upon the bioactive and pharmacological properties of current BACE1 inhibitors. Then, the molecular docking simulation models the candidate inhibitors and identifies 14 candidate drugs that exhibit stronger binding interactions to the BACE1 active site than previous candidate BACE1 drugs from clinical trials. Overall, the framework successfully discovers BACE1 inhibitors and candidate AD drugs, accelerating the developmental process for a novel AD treatment.
BibTeX
@misc{xie2024ai,
  author = {Evan Xie and Karin Hasegawa and Georgios Kementzidis and Evangelos Papadopoulos and Bertal H. Aktas and Yuefan Deng},
  title = {{An AI-Driven Framework for Discovery of BACE1 Inhibitors for Alzheimer’s Disease}},
  year = {2024},
  doi = {10.1101/2024.05.15.594361},
  howpublished = {bioRxiv},
}
Figure